Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Non Operating Income (2018 - 2025)

Serina Therapeutics' Non Operating Income history spans 8 years, with the latest figure at $35000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 99.48% year-over-year to $35000.0; the TTM value through Sep 2025 reached $3.0 million, down 81.88%, while the annual FY2024 figure was $5.8 million, 30.45% down from the prior year.
  • Non Operating Income for Q3 2025 was $35000.0 at Serina Therapeutics, up from -$897000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $13.4 million in Q4 2023 and bottomed at -$12.7 million in Q1 2024.
  • The 5-year median for Non Operating Income is $35000.0 (2025), against an average of $1.0 million.
  • The largest YoY upside for Non Operating Income was 6276.19% in 2024 against a maximum downside of 584.5% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$292000.0 in 2021, then crashed by 235.27% to -$979000.0 in 2022, then soared by 1463.74% to $13.4 million in 2023, then crashed by 79.05% to $2.8 million in 2024, then crashed by 98.75% to $35000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Non Operating Income are $35000.0 (Q3 2025), -$897000.0 (Q2 2025), and $1.0 million (Q1 2025).